Zydus Lifesciences’ venture arm invests in Illexcor Therapeutics for sickle cell disease therapies

Share it

Shares of Zydus Lifesciences Ltd ended at ₹889.00, down by ₹10.90, or 1.21%, on the BSE.

Leave a Comment

Your email address will not be published. Required fields are marked *